RBC Capital Upgrades Cardiome Pharma (CRME) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/31/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts CRME Hot Sheet
Price: $2.33 --0%
Rating Summary:
8 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
8 Buy, 2 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
RBC Capital upgraded Cardiome Pharma (NASDAQ: CRME) from Sector Perform to Outperform. PT increased to $8.40.
For more ratings news on Cardiome Pharma click here and for the rating history of Cardiome Pharma click here.
Shares of Cardiome Pharma closed at $4.41 yesterday.
For more ratings news on Cardiome Pharma click here and for the rating history of Cardiome Pharma click here.
Shares of Cardiome Pharma closed at $4.41 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- RBC Capital Upgrades Wesfarmers Ltd. (WES:AU) (WFAFF) to Sector Perform
- Goldman Sachs Upgrades Chow Tai Fook Jewellery Group Ltd. (1929:HK) (CJEWF) to Buy
- Pinterest Inc (PINS) PT Lowered to $22 at RBC Capital
Create E-mail Alert Related Categories
UpgradesRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
